GLK-33 is a CD33+ antibody-drug conjugate (ADC). GLK-33 binds to human CD33 with an EC 50 value between 200 and 400 pM. GLK-33 consists of the humanized anti-CD33 antibody Lintuzumab (HY-P9983), and the drug-linker conjugate being mavg-MMAU (HY-185154). GLK-33 shows target-specific antibody-dependent cellular cytotoxicity (ADCC) activity and complement-dependent cytotoxicity (CDC) activity against CD33-positive leukemia cell lines. GLK-33 reduces cell viability within CD33-positive leukemia and multidrug-resistant cells. GLK-33 demonstrates antitumor activity in vivo. GLK-33 can be used for acute myeloid leukemia (AML) research[1].
